Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.

Journal for Immunotherapy of Cancer
Yousef ZakhariaMohammed Milhem

Abstract

The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan (Trp) and high kynurenine (Kyn) that result from IDO activity. In this study, indoximod was used in combination with a checkpoint inhibitor (CPI) pembrolizumab for the treatment for advanced melanoma. Patients with advanced melanoma were enrolled in a single-arm phase II clinical trial evaluating the addition of indoximod to standard of care CPI approved for melanoma. Investigators administered their choice of CPI including pembrolizumab (P), nivolumab (N), or ipilimumab (I). Indoximod was administered continuously (1200 mg orally two times per day), with concurrent CPI dosed per US Food and Drug Administration (FDA)-approved label. Between July 2014 and July 2017, 131 patients were enrolled. (P) was used more frequently (n=114, 87%) per investigator's choice. The efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P).The objective response rate (ORR) for the evaluable populat...Continue Reading

References

Aug 15, 2012·Immunological Reviews·Tracy L McGahaAndrew L Mellor
Jun 12, 2013·The Journal of Experimental Medicine·Rikke B HolmgaardJames P Allison
Aug 30, 2013·Science Translational Medicine·Stefani SprangerThomas F Gajewski
Apr 3, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Derek A WainwrightMaciej S Lesniak
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Sep 29, 2015·Cell Reports·Rikke B HolmgaardJedd D Wolchok
Mar 24, 2016·Oncotarget·Hatem H SolimanScott J Antonia
Sep 12, 2018·Seminars in Immunopathology·Alexander J MullerGeorge C Prendergast

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.